Keros TherapeuticsKROS
KROS
About: Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Employees: 163
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]
20% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 40
0.13% less ownership
Funds ownership: 90.72% [Q4 2024] → 90.59% (-0.13%) [Q1 2025]
2% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 50
3% less funds holding
Funds holding: 161 [Q4 2024] → 156 (-5) [Q1 2025]
26% less capital invested
Capital invested by funds: $582M [Q4 2024] → $429M (-$153M) [Q1 2025]
27% less call options, than puts
Call options by funds: $12.5M | Put options by funds: $17M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
11%
upside
Avg. target
$22
61%
upside
High target
$26
92%
upside
5 analyst ratings
3 positive
60%
2 neutral
40%
0 negative
0%
B of A Securities Jason Zemansky | 33%upside $18 | Neutral Downgraded | 10 Jun 2025 |
Wedbush Yun Zhong | 11%upside $15 | Neutral Reiterated | 30 May 2025 |
Scotiabank Greg Harrison | 92%upside $26 | Sector Outperform Maintained | 12 May 2025 |
HC Wainwright & Co. Andrew Fein | 84%upside $25 | Buy Maintained | 8 May 2025 |
Truist Securities Srikripa Devarakonda | 84%upside $25 | Buy Maintained | 9 Apr 2025 |
Financial journalist opinion
Based on 6 articles about KROS published over the past 30 days
Neutral
PRNewsWire
5 days ago
ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal
Significant Withhold Votes from Directors Mary Ann Gray and Alpna Seth Underscores Need for Change and a More Disciplined Capital Allocation Strategy AUSTIN, Texas , June 9, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company"), today issued the following statement regarding the results of the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"): "We believe the outcome of the Annual Meeting underscores what we have consistently conveyed to Keros' Board of Directors: there is broad and growing concern among stockholders regarding the Board's capital allocation decisions and fidelity to stockholder interests. ADAR1 previously disclosed its intention to withhold votes from Dr. Mary Ann Gray and Dr. Alpna Seth at the Annual Meeting.
Neutral
GlobeNewsWire
6 days ago
Keros Announces Return of $375 Million in Excess Capital to Stockholders
Concludes Strategic Alternatives Review and Provides Update on Development of KER-065 Concludes Strategic Alternatives Review and Provides Update on Development of KER-065
Neutral
GlobeNewsWire
1 week ago
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 a.m. Eastern time.
Neutral
GlobeNewsWire
2 weeks ago
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced topline data from the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (“PAH”), and provided a corporate update.
Neutral
GlobeNewsWire
2 weeks ago
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees
Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process
Neutral
PRNewsWire
3 weeks ago
ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth
ADAR1 Urges Board to Release Strategic Review Results Before, Not After, Annual Meeting AUSTIN, Texas , May 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has recommended that Keros stockholders WITHHOLD votes from incumbent directors Dr. Mary Ann Gray and Dr. Alpna Seth at the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting"), scheduled for June 4, 2025. In its report, ISS raised serious concerns regarding the Company's governance and concluded that greater accountability at Keros is needed.
Neutral
PRNewsWire
1 month ago
ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth
AUSTIN, Texas , May 12, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released an investor presentation outlining its rationale for withholding votes on the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the Keros Board of Directors at the Company's upcoming Annual Meeting of Stockholders, scheduled for June 4, 2025. The presentation can be viewed here.
Neutral
GlobeNewsWire
1 month ago
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S.
Neutral
GlobeNewsWire
1 month ago
Keros Reinforces Commitment to Maximizing Stockholder Value
Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today issued the following statement in response to the misleading press release issued by ADAR1 Capital Management (“ADAR1”) regarding Keros' upcoming 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”), currently scheduled for June 4, 2025: The Board is committed to acting in the best interests of the Company and all of its stockholders.
Neutral
PRNewsWire
1 month ago
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth AUSTIN, Texas , May 8, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released a public letter to fellow Keros stockholders outlining its concerns with the Company's capital allocation decisions, strategic direction, and prolonged underperformance. In the letter, ADAR1 details the Company's alarming clinical results for two of its three drug candidates — KER-012 and KER-065 — and expresses serious concern that continued investment in these programs risks further shareholder value destruction.
Charts implemented using Lightweight Charts™